Skip to content
Company Analysis

Fulgent Genetics, Inc. FLGT

A comprehensive view of key metrics, scores, and financial health for Fulgent Genetics, Inc.

Overview of Fulgent Genetics, Inc.

FLGT NGM
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Small Cap
Fulgent Genetics, Inc. (FLGT), is a Small Cap company, in the Diagnostics & Research industry, last closed at $18.68, about 32.9% overvalued vs fair value, -9.7% 1Y return, ranked 682/1122 in sector.
Metrics Rev Growth 13.8% ROE -5.4% Gross Margin 40.6%
USD 18.68
-0.53%
(Delayed)
• Vol 90d: 93.2%
52-Week Range
Market Cap
$537.60M
Enterprise Value
$487.88M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 55%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.fulgentgenetics.co...
HQ El Monte, CA
Employees 1,313
Fiscal year Dec 31

Next Events

Earnings Jul 31 Estimated

Fair Value Snapshot

Bear Base Bull
$10
$13
$15
Current: $18.68 -33% vs base

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$322.7M
13.8%%
Gross Profit
$130.9M
22.1%%
Operating Income (GAAP)
$-61.6M
16.6%%
EBITDA
$-45.8M
6.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
40.6%
Fair

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
5
Active Leaks
0/5
Improving
0
High Impact
4
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Fulgent Genetics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
35
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Weak
24
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing FLGT's balance between Growth (37.3%), Profitability (34.5%), and Safety (28.2%). Growth 37% Safety 28% Profitability 35%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

51th percentile vs peers
51
Key Signals
Rev Growth YoY 13.8% 65p EPS Growth YoY 74.9% 82p Revenue CAGR 3Y -19.5% 8p
Strengths
  • EPS Growth YoY in top 20% of peers (74.9%, 82th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Current Ratio in top 20% of peers (6.48, 84th percentile)
  • Quick Ratio in top 20% of peers (4.74, 81th percentile)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

47th percentile vs peers
48
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

38th percentile vs peers
39
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Fulgent Genetics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$12.54
- - -
-32.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000